VCAM-1 complements CA-125 in detecting recurrent ovarian cancer

Clinical Proteomics

Research

Daniel W. Chan¹  Zhen Zhang¹  Lori J. Sokoll¹  Jin Song² 

[1] Center for Biomarker Discovery and Translation, Department of Pathology, Johns Hopkins University School of Medicine, 21287, Baltimore, MD, USA;Department of Oncology, Johns Hopkins University School of Medicine, 21287, Baltimore, MD, USA;Center for Biomarker Discovery and Translation, Department of Pathology, Johns Hopkins University School of Medicine, 21287, Baltimore, MD, USA;Department of Pathology, Johns Hopkins University School of Medicine, 419 North Caroline Street, 21231, Baltimore, MD, USA;

关键词: Ovarian cancer;    Recurrent;    Serum;    Biomarker;    Multiplex immunoassay;   

DOI  :  10.1186/s12014-023-09414-z

 received in 2022-11-01, accepted in 2023-06-13,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundClose to three-quarters of ovarian cancer cases are frequently diagnosed at an advanced stage, with more than 70% of them failing to respond to primary therapy and relapsing within 5 years. There is an urgent need to identify strategies for early detection of ovarian cancer recurrence, which may lead to earlier intervention and better outcomes.MethodsA customized magnetic bead-based 8-plex immunoassay was evaluated using a Bio-Plex 200 Suspension Array System. Target protein levels were analyzed in sera from 58 patients diagnosed with advanced ovarian cancer (including 34 primary and 24 recurrent tumors) and 46 healthy controls. The clinical performance of these biomarkers was evaluated individually and in combination for their ability to detect recurrent ovarian cancer.ResultsAn 8-plex immunoassay was evaluated with high analytical performance suitable for biomarker validation studies. Logistic regression modeling selected a two-marker panel of CA-125 and VCAM-1 that improved the performance of CA-125 alone in detecting recurrent ovarian cancer (AUC: 0.813 versus 0.700). At a fixed specificity of 83%, the two-marker panel significantly improved sensitivity in separating primary from recurrent tumors (70.8% versus 37.5%, P = 0.004), demonstrating that VCAM-1 was significantly complementary to CA-125 in detecting recurrent ovarian cancer.ConclusionsA two-marker panel of CA-125 and VCAM-1 showed strong diagnostic performance and improvement over the use of CA-125 alone in detecting recurrent ovarian cancer. The experimental results warrant further clinical validation to determine their role in the early detection of recurrent ovarian cancer.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

13690_2023_1130_Article_IEq12.gif

13690_2023_1130_Article_IEq9.gif